ESMO Prospect The next generation of immunological innovation therapies, who can take the baton?

The 2022 European Society for Internal Oncology (ESMO) Annual Meeting will be held
in Paris from September 9 to 13 local time.

LBA37: Randomized, multicenter phase II study (NEOpredict-Lung) of patients with resectable NSCLC who received navurizumab monotherapy or combined with Relatlimab (LAG-3 inhibitor)

：A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)

Speaker: Martin H.

Time: September 9, 16:00 - 16:10

LAG-3 is one of the members of the immunoglobulin superfamily and is mainly expressed on the surface of T cells, which can negatively regulate T cell proliferation and effector T cell function
.

LBA38-BNT211-01: Phase I studies assess the safety and efficacy of CLDN6 CAR-T cell therapy and CLDN6-encoding RNA vaccine (CARVac) amplified by CAR-T cells in patients with CLDN6-positive advanced solid tumors

：BNT211-01: A Phase 1 trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours

Speaker: Andreas Mackensen (Germany)

Time: September 9, 16:30 - 16:40

CLDN-6 belongs to a family of membrane proteins involved in the formation of tight junctions (cell junctions) in cell adhesion and the occurrence and development
of cancer.

Phase I dose escalation results from 728O-IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein applied to solid tumors

：Results from Phase 1 dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors

Speaker: Omid Hamid (USA)

Time: September 9, 9:16 - 40:16

IMC-F106C is an ImmTAC molecule that targets the HLA-A*02:01 genotype, the PROME antigen
.
In tumor immunotherapy, the bispecific nature of ImmTAC allows it to "preheat" cold solid tumors by recruiting and activating non-cancer-specific T cells, overcoming the problem
of insufficient number of immune cells in the tumor microenvironment or low immunogenicity of some tumors.
In addition, ImmTAC has a larger pool of potential targets that can utilize target proteins that are not expressed on healthy cells or at the lowest level, thereby reducing or avoiding the problem of
immune tolerance in tumor immunotherapy.
Moreover, compared to other antibodies or cell therapies, ImmTAC does not require pretreatment to treat attack tumors
immediately.
Phase 1 clinical data
on IMC-F106C in multiple solid tumors, including breast, endometrium, ovarian and small cell lung cancers, will be presented at the ESMO conference.

730MO-INCAGN02390, a TIM-3 inhibitor for patients with advanced malignancy, is the first human Phase 1 study

：First In Human Phase 1 Study of INCAGN02390, a TIM-3 Monoclonal Antibody Antagonist in Patients With Advanced Malignancies

Speaker: Martin E.
Gutierrez (USA)

Time: September 9, 10:14 - 50:14

TIM-3 is a class of T cell surface inhibitory molecules that can exert immunosuppressive effects
by inhibiting T helper cells (Th1 and Th17), inducing CD8+ T cell depletion, and promoting Treg cells to become immunosuppressed cell populations.
The TIM-3 target is an effective target for tumor immunotherapy, and its expression is related to the poor prognosis of the tumor and is related
to PD-1 resistance.
Anti-TIM-3 monoclonal antibody can play a synergistic role with CTLA-4, PD-1 and PD-L1 antibodies, and can treat PD-1 and PD-L1 resistant patients, and further clinical findings
are expected.

737MO - CAR-T cells targeted at EpCAM for the treatment of patients with advanced coloral and gastric cancer

：EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers

Speaker: Fang Weijia (First Affiliated Hospital of Zhejiang University School of Medicine)

Time: September 9, 10:15 - 55:16

EpCAM is highly expressed in a variety of epithelial cell-derived tumors, especially in digestive malignancies, and the expression is uniform (90% expression rate), which is an effective target for such advanced tumors
.
CAR-T therapy has made great progress in the treatment of a variety of hematological malignancies in recent years, but due to the heterogeneity of solid tumors themselves, the research and application of CAR-T therapy in solid tumors still faces many challenges
.
Can EpCAM CAR-T Therapy Stand Out? The results
presented at the ESMO conference are expected.

Stay tuned:

The overseas team of Yimaitong will go to the ESMO site to bring you first-hand fresh information and real-time reports of the 2022 ESMO Conference, so stay tuned!